Ana André

Dr. Ana André

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Sandra AguiarSandra Aguiar
Sandra Aguiar
Joana N. R. DiasJoana N. R. Dias
Joana N. R. Dias
AAAna André
Ana André
MSMarta Lisete Silva
Marta Lisete Silva
DMDiana Ferreira Martins
Diana Ferreira Martins
FSFrederico Aires Da Silva
Frederico Aires Da Silva
A major bottleneck in the successful development of central nervous system (CNS) drugs is the discovery and design of molecules that can cross the blood-brain barrier (BBB). Nano-delivery strategies are a promising approach that take advantage of natural portals of entry into the brain such as monoclonal antibodies (mAbs) targeting endogenous BBB receptors. However, the main selected mAbs rely on targeting broadly expressed receptors, such as the transferrin and insulin receptors, and in selection processes that do not fully mimic the native receptor conformation, leading to mistargeting and a low fraction of the administered dose effectively reaching the brain. Thus, there is an urgent need to identify new BBB receptors and explore novel antibody selection approaches that can allow a more selective delivery into the brain. Considering that in vitro models fail to completely mimic brain structure complexity, we explored an in vivo cell immunization approach to construct a rabbit derived single-domain antibody (sdAb) library towards BBB endothelial cell receptors. The sdAb antibody library was used in an in vivo phage display screening as a functional selection of novel BBB targeting antibodies. Following three rounds of selections, next generation sequencing analysis, in vitro brain endothelial barrier (BEB) model screenings and in vivo biodistribution studies, five potential sdAbs were identified, three of which reaching >0.6% ID/g in the brain. To validate the brain drug delivery proof-of-concept, the most promising sdAb, namely RG3, was conjugated at the surface of liposomes encapsulated with a model drug, the pan-histone deacetylase inhibitor panobinostat (PAN). The translocation efficiency and activity of the conjugate liposome was determined in a dual functional in vitro BEB-glioblastoma model. The RG3 conjugated PAN liposomes enabled an efficient BEB translocation and presented a potent antitumoral activity against LN229 glioblastoma cells without influencing BEB integrity. In conclusion, our in vivo screening approach allowed the selection of highly specific nano-antibody scaffolds with promising properties for brain targeting and drug delivery.

19 June 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
Joana N. R. DiasJoana N. R. Dias
Joana N. R. Dias
Sandra AguiarSandra Aguiar
Sandra Aguiar
DPDiane M. Pereira
Diane M. Pereira
AAAna André
Ana André
Lurdes GanoLurdes Gano
Lurdes Gano
FSFrederico Aires Da Silva
Frederico Aires Da Silva
The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma

1 July 2017 in Journal of Biotechnology
Verified
Journal Article
Closed access
CCCátia Cantante
Cátia Cantante
SLSara Lourenço
Sara Lourenço
MMMauricio Morais
Mauricio Morais
JLJoão Leandro
João Leandro
Lurdes GanoLurdes Gano
Lurdes Gano
João GonçalvesJoão Gonçalves
João Gonçalves

28 December 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Joana N. R. DiasJoana N. R. Dias
Joana N. R. Dias
AAAna André
Ana André
Sandra AguiarSandra Aguiar
Sandra Aguiar
JMJoana Ministro
Joana Ministro
JOJoana Oliveira
Joana Oliveira
FSFrederico Aires Da Silva
Frederico Aires Da Silva
Canine diffuse large B-cell lymphoma (DLBCL) is one of the most common cancers in dogs which shares remarkable similarities with its human counterpart, making the dog an excellent model for the investigation of novel therapeutic agents. However, the integration of canine lymphoma in comparative studies has been limited due in part to the lack of suitable xenograft mouse models for preclinical studies. To overcome these limitations, we established and characterized a localized subcutaneous bioluminescent canine DLBCL xenograft mouse model. The canine CLBL-1 cell line stably expressing the luciferase and green fluorescent protein reporters was generated and used to establish the xenograft tumor model. A pilot study was first conducted with three different cell densities (0.1×106, 0.5×106 and 1×106 cells) in SCID mice. All mice presented homogeneous tumor induction within eight days after subcutaneous injection, with a 100% engraftment efficiency and no significant differences were observed among groups. The tumors were highly aggressive and localized at the site of inoculation and reproduced histological features and immunophenotype consistent with canine DLBCL. Importantly, xenograft tumors were detected and quantified by bioluminescent imaging. To assess response to therapy, a therapeutic study with a histone deacetylase inhibitor, panobinostat, was performed. The results demonstrated that panobinostat (20 mg/kg) efficiently inhibited tumor growth and that bioluminescent imaging allowed the monitorization and quantification of tumor response to therapy. In summary, this study provides a bioluminescence canine DLBCL model that offers high engraftment efficiency, preservation of tumor features, and noninvasive monitoring of tumor progression, validating the model as a promising preclinical tool for both veterinary and human medicine.